Enzyme with high potential for new cancer treatment identified
Several essential processes take place in separate compartments within a cell. The cell’s most important asset, DNA, is packed inside the cell nucleus, and a veritable armada of proteins is responsible for the organisation, replication and protection of the DNA. Many of these proteins perform a number of tasks, for instance possessing functions at the replication fork and repairing damage to DNA. Most of the mechanisms for the individual functions of these proteins are understood, but there has as yet been little research into the coordination and regulation between the various processes.
Biologists at the TU Darmstadt under Prof. Dr. Markus Löbrich and Dr. Julian Spies have collaborated with their colleagues at the University of California in Davis and identified a protein kinase called Nek1 that promotes the repair of DNA double-strand breaks and separates this repair from replication. Nek1 switches on the motor protein Rad54 only after the completion of replication in order to finalize the repair process. This is of physiological relevance because during replication, Rad54 possesses additional functions at the replication fork, and premature activation of Rad54 results in a major disturbance of the replication process, report the Darmstadt-based researchers in the research journal Molecular Cell.
Use in cancer treatment
This discovery has a very high potential for use in the development of entirely new kinds of cancer treatments. Finding inhibitors that block the function of Nek1 would lead to a loss in the repair function. Tumour cells in particular would suffer from this loss of function in Nek1, since they experience a tremendous amount of DNA damage during their uncontrolled growth. The scientists suspect that the inhibition of Nek1 could be associated with an accumulation of unrepaired DNA damage in these cells that could cause the tumour cells to die. The team of researchers plans to continue to investigate these assumptions over the coming years.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.